Current challenges in the pharmacological management of genitourinary syndrome of menopause

References

• Marino JM. Genitourinary syndrome of menopause. Journal of Midwifery & Women’s Health. 2021;66(6):729–739.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass MLS. Vulvovaginal atrophy terminology consensus conference panel. genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and The North American Menopause Society. Maturitas. 2014;79(3):349–354.
   PubMed Web of Science ®Google Scholar
• Takahashi TA, Johnson KM. Menopause. Med Clin North Am. 2015;99(3):521–534.
   PubMed Web of Science ®Google Scholar
• Keil K. Urogenital atrophy: diagnosis, sequelae, and management. Curr Womens Health Rep. 2002;2(4):305–311.
   PubMedGoogle Scholar
• Palma F, Volpe A, Villa P, et al. Vaginal atrophy of women in postmenopause. Results from a multicentric 358 observational study: the AGATA study. Maturitas. 2016;83:40–44.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Krychman M, Graham S, et al. The women’s EMPOWER survey: identifying women’s 362 perceptions on vulvar and vaginal atrophy and its treatment. J Sex Med. 2017;14:413–424.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA) – results from an international 364 survey. Climacteric. 2012;15:36–44.
   PubMed Web of Science ®Google Scholar
• Working Group on Women’s Health and Well-Being in Menopause, Manson JE, Goldstein SR, Kagan R, et al. Why the product labeling for low-dose vaginal estrogen should be changed. Menopause. 2014;21(9):911.
   PubMed Web of Science ®Google Scholar
• Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause 373 Society. Menopause. 2020;27:976–992.
   PubMed Web of Science ®Google Scholar
• The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2018 Nov;25(11):1362–1387.
   PubMed Web of Science ®Google Scholar
• Da Silva AS, Baines G, Araklitis G, et al. Management of genitourinary syndrome of menopause. Faculty Reviews. 2021.
   PubMedGoogle Scholar
• Potter N, Panay N. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety. Climacteric. 2021 Feb;24(1):19–24.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Cucinella L, Martini E, et al. The role of hormone therapy in urogenital health after menopause. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101595.
   PubMed Web of Science ®Google Scholar
• Pitkin J. British Menopause Society medical advisory council. BMS - Consensus Statement. Post Repod Health. 2018;24(3):133–138.
   PubMedGoogle Scholar
• Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause. Obstet Gynecol. 2014;124(6):1147–1156.
   PubMed Web of Science ®Google Scholar
• Li B, Duan H, Chang Y, et al. Efficacy and safety of current therapies for genitourinary syndrome of menopause: a Bayesian network analysis of 29 randomized trials and 8311 patients. Pharmacol Res. 2021;164(October 2020):105360.
   PubMedGoogle Scholar
• Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;2016(8).
   Google Scholar
• Glaser RL, Zava DT, Wurtzbacher D. Pilot study: absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina. Gynecol Obstet Invest. 2008;66(2):111–118.
   PubMed Web of Science ®Google Scholar
• Donders GGG, Ruban K, Bellen G, et al. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019;20(7):821–835.
   PubMed Web of Science ®Google Scholar
• Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20:888–902; quiz 903–4.
   Web of Science ®Google Scholar
• Kovachev SM, Kovachev MS. Genitourinary syndrome, local oestrogen therapy and endometrial pathology: a single-centre, randomised study.J Obstet Gynaecol J Inst Obstet Gynaecol.2022;Jan 1–4.
   Google Scholar
• Constantine GD, Graham S, Lapane K, et al. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause. 2019;26:800–807.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the women’shealth initiative observational study. Menopause. 2018 Jan;25:11–20.
   PubMedGoogle Scholar
• Villa P, Tagliaferri V, Amar ID, et al. Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment. Gynecol Endocrinol. 2020 Jun;36(6):535–539.
   PubMed Web of Science ®Google Scholar
• Group C, Cancer B. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168.
   PubMed Web of Science ®Google Scholar
• Laing AJ, Newson L, Simon JA. Individual benefits and risks of intravaginal estrogen and systemic testosterone in the management of women in the menopause, with a discussion of any associated risks for cancer development. Cancer J. 2022;28(3):196–203.
   PubMed Web of Science ®Google Scholar
• Hamoda H, Panay N, Pedder H, et al. on behalf of the Medical Advisory Council of the British Menopause Society. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Heal. 2020;26(4):181–209.
   PubMedGoogle Scholar
• López DML. Management of genitourinary syndrome of menopause in breast cancer survivors: an update. World J Clin Oncol. 2022;13(2):71–100.
   PubMed Web of Science ®Google Scholar
• Svendsen ALO, Esbech PS, Nielsen E, et al. Does administration of vaginal estrogens increase the risk of venous thromboembolism: a case–control study. Basic Clin Pharmacol Toxicol. 2021;129(5):385–388.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of treatment options for menopausal vaginal changes) survey. J Sex Med. 2013;10(7):1790–1799.
   PubMed Web of Science ®Google Scholar
• Paciuc J. Hormone therapy in menopause. Adv Exp Med Biol. 2020;1242:89–120.
   PubMed Web of Science ®Google Scholar
• Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone re- placement therapy and the primary prevention of cardiovascular disease. Ann Intern Med. 2002;137:273–284.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the hormones and urogenital therapy committee. Obstet Gynecol. 1998;92(4 Pt 2):722.
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women’s Health Initiative Investigators, Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321.
   PubMed Web of Science ®Google Scholar
• Hamoda H, Panay N, Pedder H, et al. The British Menopause Society & Women’s Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reprod Health. 2020 Dec;26(4):181–209.
   PubMedGoogle Scholar
• Col NF. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol. 2001;19(8):2357.
   PubMed Web of Science ®Google Scholar
• Holmbeg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008 [Epub 2008 Mar 25];100(7):475.
   PubMedGoogle Scholar
• Fahlén M. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2013 Jan;49(1):52–59. Epub 2012 Aug 11.
   PubMed Web of Science ®Google Scholar
• Billeci AM, Paciaroni M, Caso V, et al. Hormone replacement therapy and stroke. Curr Vasc Pharmacol. 2008 Apr;6(2):112–123.
   PubMed Web of Science ®Google Scholar
• Fournier O, Berrino A, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008 Jan;107(1):103–111.
   PubMed Web of Science ®Google Scholar
• Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas. 2016 Sep;91:25–35.
   PubMed Web of Science ®Google Scholar
• Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014 Jul;142:155–170.
   PubMed Web of Science ®Google Scholar
• Shi LF, Wu Y, Li CY. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis. Menopause. 2016 Apr;23(4):417–424.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007 Apr 4;297(13):1465–1477.
   PubMed Web of Science ®Google Scholar
• Labrie F, Bélanger A, Pelletier G, et al. Science of intracrinology in postmenopausal women. Menopause. 2017 Jan-Jun;24(6):702–712.
   PubMedGoogle Scholar
• Portman DJ, Goldstein SR, Kagan R. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review. Climacteric. 2019;22(1):65–72.
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol. 2008;111:178–194.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause. 2009;16:897–906.
   PubMed Web of Science ®Google Scholar
• VVA Prasterone Research Group, Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243.
   PubMed Web of Science ®Google Scholar
• Labrie F, Derogatis L, Archer DF, et al. Members of the VVA prasterone research group. effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401.
   PubMed Web of Science ®Google Scholar
• Bouchard C, Labrie F, Archer DF, et al. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric. 2015;18(4):590–607.
   PubMed Web of Science ®Google Scholar
• Ke Y, Labrie F, Gonthier R, et al. Other participating members of the prasterone clinical research group serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration. J Steroid Biochem Mol Biol. 2015 Nov;154:186–196. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976.
   PubMed Web of Science ®Google Scholar
• Shin JJ, Kim SK, Lee JR, et al. Ospemifene: a novel option for the treatment of vulvovaginal atrophy. J Menopausal Med. 2017 Aug;23(2):79–84.
   PubMedGoogle Scholar
• Simon J, Portman D, Mabey RG Jr. Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and vaginal atrophy in hysterectomized postmenopausal women. Maturitas. 2014;77:274–281.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20:623–630.
   PubMed Web of Science ®Google Scholar
• McCall JL, DeGregorio MW. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol. 2010;6:773–779.
   PubMed Web of Science ®Google Scholar
• Portman D, Palacios S, Nappi RE, et al. Ospemifene, a non-oestrogen selective oestrogen receptor modultor for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas. 2014 Jun;78(2):91–98.
   Web of Science ®Google Scholar
• Nappi RE, Panay N, Bruyniks N, et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2015;18:233–240.
   PubMed Web of Science ®Google Scholar
• Ospemifene for vulvar and vaginal atrophy. Drug Ther Bull. 2019 Jun;57(6):89–92.
   PubMedGoogle Scholar
• Pinkerton JV, Kagan R. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use. Expert Opin Pharmacother. 2015;16(17):2703–2714.
   PubMed Web of Science ®Google Scholar
• Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy. Maturitas. 2019 Mar;121:86–92.
   PubMed Web of Science ®Google Scholar
• Schiavi MC, Sciuga V, Giannini A, et al. : overactive bladder syndrome treatment with ospemifene in menopausal patients with vulvovaginal atrophy: improvement of sexuality? Gynecol Endocrinol. 2018;34(8):666–669.
   PubMed Web of Science ®Google Scholar
• Palacios S. Ospemifene for vulvar and vaginal atrophy: an overview. Drugs Context. 2020 Jul 1;9: 2020-3-2.
   Google Scholar
• Bachmann GA, Komi JO, Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010 May; 17(3):480–486.
   PubMed Web of Science ®Google Scholar
• Rutanen EM, Heikkinen J, Halonen K, et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause. 2003 Sep;10(5):433–439.
   PubMed Web of Science ®Google Scholar
• Simon JA, Lin VH, Radovich C, et al. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20(4):418.
   PubMed Web of Science ®Google Scholar
• Goldstein S, Bachmann G, Lin V, et al. Endometrial safety profile of ospemifene 60 mg when used for long-term treatment of vulvar and vaginal atrophy for up to 1 year (abstract). Climacteric. 2011;14:S57.
   Google Scholar
• Eigeliene N, Kangas L, Hellmer C, et al. Effects of ospemifene, a novel selective estrogen-receptor modulator, on human breast tissue ex vivo. Menopause. 2016 Jul;23(7):719–730.
   PubMed Web of Science ®Google Scholar
• Foschi C, Alvisi S, Baldassarre M, et al. Vaginal metabolites in postmenopausal women with or without vulvo-vaginal atrophy at baseline and after ospemifene and systemic hormone treatment. Maturitas. 2022 May;159:7–14.
   PubMed Web of Science ®Google Scholar